| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers T > Headlines for TopoTarget AS > News item |
CuraGen, TopoTarget: Southwest Oncology Group starts lymphoma trial
By Elaine Rigoli
Tampa, Fla., Aug. 24 - CuraGen Corp. and TopoTarget A/S announced the Southwest Oncology Group has just opened a phase 2 clinical trial to test the effects of a new investigational agent on aggressive B-cell lymphoma.
The agent, PXD101, will be evaluated in patients whose previous treatment regimen did not work or whose cancer returned after treatment. The trial, also known as S0520, is sponsored by the National Cancer Institute under a clinical trials agreement signed with CuraGen.
Study leaders would like to enroll up to 40 patients with refractory aggressive diffuse large, high-grade Burkitt's or Burkitt's-like or primary mediastinal B-cell lymphoma for the trial. So far, 81 Southwest Oncology Group institutions are participating in the trial.
Patients enrolled in the trial will receive PXD101 intravenously in three-week cycles. The primary goal of this study is to evaluate the response rate for patients receiving treatment with PXD101. In addition, correlative studies will be performed on some of the patients to assess histone acetylation and potential biomarkers.
"HDAC inhibitors are believed to target DNA and lead to reactivating genes that suppress tumors. Since this may slow the growth and survival of tumor cells, we are very interested in investigating PXD101 to assess its potential benefit for patients with B-Cell lymphoma," study coordinator Steven H. Bernstein said in a news release.
CuraGen is a biopharmaceutical company based in Branford, Conn.
TopoTarget is a biopharmaceutical company based in Denmark and with subsidiaries in the United Kingdom and Germany.
The Southwest Oncology Group is a cancer clinical trials cooperative research group located at the University of Michigan in Ann Arbor, Mich.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.